Virax Biolabs Group Ltd Stock Price, News & Analysis

Virax Biolabs Group (Nasdaq: VRAX) announced a private placement to raise gross proceeds of approximately $5.0 million through the sale of 12,500,000 ordinary shares (or equivalents) and associated preferred investment options at $0.40 per share. The preferred investment options are exercisable immediately for five years from the effective date of an Initial Registration Statement. Closing is expected on or about December 4, 2025, subject to customary conditions. H.C. Wainwright is the exclusive placement agent. The company said net proceeds will be used for working capital and general corporate purposes. Virax agreed to file and seek effectiveness of a resale registration statement for the issued securities within specified timing and to repricing/extend prior Series A and B preferred options to the same terms.

Virax Biolabs (NASDAQ: VRAX) reported clinical and operational progress and outlined 2026 priorities focused on its ViraxImmune™ T cell diagnostic programme for post-acute infection syndromes (PAIS).

Key facts: full recruitment completed in UK study VRX-002 (160 participants) with initial data expected in Q2 2026; second UK study VRX-003 fully enrolled (100 subjects); U.S. research collaboration with Emory University to support a planned U.S. study; ongoing expansion of the ImmuneSelect RUO product portfolio for near-term research revenue; and a debt-free balance sheet with $3.3M cash, total assets of $5.7M, liabilities of $0.6M and market capitalization of ~$1.7M.

Virax Biolabs (NASDAQ: VRAX) completed full UK recruitment for its multi-centre study of the ViraxImmune™ T cell assay in Post-Acute Infection Syndromes (PAIS), reaching the target of 160 participants in a 3:1 randomised design with 40 symptomatic patients each for Long COVID, PTLD, and ME/CFS. Clinical samples will undergo immunological analysis to evaluate assay performance to support UK regulatory filings with the MHRA and inform potential U.S. submissions.

Virax also received constructive FDA feedback from a Sept 10, 2025 pre-submission meeting and plans a U.S. clinical study with Emory University in 2026. Initial readouts are expected in Q2 2026.

Virax Biolabs (NASDAQ:VRAX) has entered into a Research Services Agreement with Emory University's ADJUST Center to conduct clinical studies of ViraxImmune™, focusing on immune profiling in post-viral syndromes, particularly long COVID (PASC).

The company is preparing for a pre-submission meeting with the FDA in early September 2025 to discuss ViraxImmune™'s regulatory pathway and intended use. Emory's Laboratory for Innovative Assay Development (ELIAD) will handle patient recruitment, testing, and analysis to generate clinical data supporting regulatory submissions.

ViraxImmune™ is a T cell testing technology that evaluates patient immune response profiles, offering potential advantages over traditional antibody testing for diagnosing chronic and post-viral conditions.

Virax Biolabs (NASDAQ:VRAX), a biotechnology company specializing in viral disease diagnostics, has appointed Dr. Iain Miller as an Independent Director effective July 29, 2025. Dr. Miller, who replaces outgoing director Yair Erez, brings over 30 years of leadership experience in diagnostics and MedTech sectors.

Dr. Miller's extensive background includes senior positions at GE Healthcare, bioMérieux, and Massachusetts General Hospital. He has founded four MedTech companies and served as CEO of Presymptom Health, where he developed InfectiClear®. His expertise spans commercial, technical, and regulatory domains, with experience serving on the UK's NICE Technology Appraisal Committee and contributing to NHS England and MHRA innovation programs.

Virax Biolabs (NASDAQ: VRAX) has received a notification from Nasdaq on July 14, 2025, regarding non-compliance with the minimum bid price requirement. The company's stock has traded below the required $1.00 minimum bid price for 30 consecutive business days.

The biotechnology company has been granted a 180-day compliance period until January 12, 2026, to regain compliance. Virax can achieve compliance if its stock maintains a closing bid price of at least $1.00 for a minimum of 10 consecutive business days. If unsuccessful, the company may be eligible for an additional 180-day grace period. Meanwhile, VRAX shares will continue trading on Nasdaq without interruption.

Virax Biolabs (NASDAQ: VRAX) has initiated patient enrollment in a UK-based, multi-center clinical study (NCT06731179) to evaluate their ViraxImmune™ FluoroSpot T cell assay. The study aims to detect T cell dysfunction in patients with post-acute infection syndromes, including:

• Long COVID
• Post-treatment Lyme disease (PTLD)
• Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS)

The clinical trial, conducted in partnership with the UK's National Health Service, will enroll up to 200 participants. Initial data from this longitudinal assessment is expected in Q2 2026. The company aims to develop reliable diagnostics for these conditions, potentially enabling earlier treatment intervention and improved patient outcomes.

Virax Biolabs (Nasdaq: VRAX) presented research data on T-Cell dysfunction in post-acute infection syndromes (PAIS) at the World Immune Regulation Meeting in Davos, Switzerland. The study demonstrated that repeated stimulation of peripheral blood mononuclear cells with SARS-CoV-2 and CMV peptide pools increases the expression of exhaustion markers in CD4⁺ and CD8⁺ T-Cells.

The research showed that T-Cell exhaustion correlates with reduced cytokine production, particularly pro-inflammatory cytokines, leading to impaired immune functionality. Preliminary data from the ViraxImmune™ PAIS assay revealed significant differences in cytokine levels between PAIS patients and healthy controls.

The company has initiated clinical validation studies to evaluate their T-Cell-based diagnostic's performance in assessing the relationship between T-Cell dysfunction and symptoms like chronic fatigue and cognitive impairment in conditions such as long COVID, ME/CFS, and chronic Lyme disease.

Virax Biolabs (Nasdaq: VRAX) has announced its participation in the prestigious 19th World Immune Regulation Meeting (WIRM) taking place March 12-15, 2025, in Davos, Switzerland. The company's Chief Operating Officer, Dr. Nigel McCracken, will deliver a presentation titled 'Evaluation of T cell dysfunction in post acute infection syndromes' on March 12, 2025, at 20:00 in Foyer A1 of The Congress Center.

The biotechnology company, focused on viral disease diagnosis and immune response detection, will also showcase its immune profiling products at Booth 116. Management will be available to engage with research organizations and potential customers during the event.

WIRM 2025 is set to bring together approximately 600 scientists and clinicians worldwide, featuring scientific lectures, networking opportunities, and a poster exhibition in Davos.